Table 4.
Outcome variables reported in the studies that have addressed the efficacy of iStent GTS-400 placement. The data provided for the present study are end-follow-up data for the 20 eyes enrolled and 5-year results for 11 eyes.
| Source | n | Combined phaco | Follow-up (months) | Mean IOP reduction (mmHg) from preop | IOP ≤ 18 mmHg w/o meds |
Mean reduction in meds |
|---|---|---|---|---|---|---|
| Arriola-Villalobos et al. [14]∗ | 20 | Yes | 12 | 3.2 ± 3.75 | 50% | 1 ± 0.79 |
| Voskanyan et al. [15] | 92 | No | 12 | 22.1 ± 3.3 versus 15.7 ± 3.7† | 66% | NA |
| Klamann et al. [16] | 17 | No | 6 | 21.19 ± 2.56 versus 14.19 ± 1.38† | NA | 2.19 ± 0.91 versus 0.88 ± 0.62† |
| Fea et al. [17] | 94 | No | 12 | 8.1 ± 2.6 | 92.6% | NA |
| Present study∗ | 20 | Yes | 47.4 ± 18.46 | 3.7 ± 3.7 | 40% | 0.6 ± 0.88 |
| 11 | 60 | 4.18 ± 4.62 | 28% | 0.09 ± 0.94 |
Preoperative IOP refers to medicated IOP. (n: number of patients; w/o: without; †data not available, mean preoperative versus mean postoperative data; ∗same set of patients; NA: not available.)